These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 39253182)

  • 1. Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primates.
    Greenberg EF; Voorbach MJ; Smith A; Reuter DR; Zhuang Y; Wang JQ; Wooten DW; Asque E; Hu M; Hoft C; Duggan R; Townsend M; Orsi K; Dalecki K; Amberg W; Duggan L; Knight H; Spina JS; He Y; Marsh K; Zhao V; Ybarra S; Mollon J; Fang Y; Vasanthakumar A; Westmoreland S; Droescher M; Finnema SJ; Florian H
    Heliyon; 2024 Aug; 10(16):e36483. PubMed ID: 39253182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells.
    Escriche-Navarro B; Garrido E; Sancenón F; García-Fernández A; Martínez-Máñez R
    Acta Biomater; 2024 Mar; 176():405-416. PubMed ID: 38185231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice.
    Sharma AK; Roberts RL; Benson RD; Pierce JL; Yu K; Hamrick MW; McGee-Lawrence ME
    Front Cell Dev Biol; 2020; 8():354. PubMed ID: 32509782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of preclinical Alzheimer's disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology.
    Huang X; Huang S; Fu F; Song J; Zhang Y; Yue F
    Alzheimers Res Ther; 2024 Mar; 16(1):52. PubMed ID: 38459540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Senolytic therapy to modulate the progression of Alzheimer's Disease (SToMP-AD) - Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease.
    Gonzales MM; Garbarino VR; Kautz T; Palavicini JP; Lopez-Cruzan M; Dehkordi SK; Mathews J; Zare H; Xu P; Zhang B; Franklin C; Habes M; Craft S; Petersen RC; Tchkonia T; Kirkland J; Salardini A; Seshadri S; Musi N; Orr ME
    Res Sq; 2023 Apr; ():. PubMed ID: 37162971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
    González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
    Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics.
    Riessland M; Orr ME
    J Prev Alzheimers Dis; 2023; 10(4):633-646. PubMed ID: 37874084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis.
    Walton CC; Begelman D; Nguyen W; Andersen JK
    Front Cell Neurosci; 2020; 14():129. PubMed ID: 32508595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astrocyte Senescence and Alzheimer's Disease: A Review.
    Han X; Zhang T; Liu H; Mi Y; Gou X
    Front Aging Neurosci; 2020; 12():148. PubMed ID: 32581763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular Senescence as the Key Intermediate in Tau-Mediated Neurodegeneration.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2018 Dec; 21(6):572-579. PubMed ID: 30489222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteostasis disruption and senescence in Alzheimer's disease pathways to neurodegeneration.
    Thapa R; Ahmad Bhat A; Shahwan M; Ali H; PadmaPriya G; Bansal P; Rajotiya S; Barwal A; Siva Prasad GV; Pramanik A; Khan A; Hing Goh B; Dureja H; Kumar Singh S; Dua K; Gupta G
    Brain Res; 2024 Dec; 1845():149202. PubMed ID: 39216694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
    Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
    J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulating
    Spina JS; Carr TL; Phillips LA; Knight HL; Crosbie NE; Lloyd SM; Jhala MA; Lam TJ; Karman J; Clements ME; Day TA; Crane JD; Housley WJ
    Aging (Albany NY); 2024 Jun; 16(13):10694-10723. PubMed ID: 38976646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Senescence Targeting Methods Impact Alzheimer's Disease Features in 3xTg Mice.
    Ng PY; Zhang C; Li H; Baker DJ
    J Alzheimers Dis; 2024; 97(4):1751-1763. PubMed ID: 38306030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.